Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer

Lasers in Surgery and Medicine

Volumn 38, Issue 5, 2006, Pages 427-434

  Du, K L ^a   Mick, R ^b   Busch, T M ^a   Zhu, T C ^a   Finlay, J C ^a   Yu, G ^c   Yodh, A G ^c   Malkowicz, S B ^a   Smith, D ^a   Whittington, R ^a   Stripp, D ^a   Hahn, S M ^a,c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adenocarcinoma; Motexafin lutetium; Photodynamic therapy; Prostate cancer

Indexed keywords

LUTETIUM TEXAPHYRIN; PHOTOSENSITIZING AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOG; DOSIMETRY; HUMAN; LIGHT; MALE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE NECROSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANIMALS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOGLOBINS; HUMANS; MALE; METALLOPORPHYRINS; MIDDLE AGED; NECROSIS; NEOPLASM RECURRENCE, LOCAL; OXYGEN; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSTATE; PROSTATIC NEOPLASMS; REGIONAL BLOOD FLOW;

EID: 33745699951     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.20341     Document Type: Article

References (56)

1. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002;20(1):3-7.
2. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst 1998;90(12):889-905.
3. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991;53(4):549-553.
4. Barr H, Tralau CJ, Boulos PB, MacRobert AJ, Tilly R, Bown SG. The contrasting mechanisms of colonic collagen damage between photodynamic therapy and thermal injury. Photochem Photobiol 1987;46(5):795-800.
5. Fielding DI, Buonaccorsi G, Cowley G, Johnston AM, Hughes /SNM> G, Hetzel MR, Bown SG. Interstitial laser photocoagulation and interstitial photodynamic therapy of normal lung parenchyma in the pig. Lasers Med Sci 2001;16(1):26-33.
6. Hsi RA, Rosenthal DI, Glatstein E. Photodynamic therapy in the treatment of cancer: Current state of the art. Drugs 1999;57(5):725-734.
7. Gomer CJ, Smith DM. Photoinactivation of Chinese hamster cells by hematoporphyrin derivative and red light. Photochem Photobiol 1980;32(3):341-348.
8. Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT. Prostate carcinoma presentation, diagnosis, and staging: An update form the National Cancer Data Base. Cancer 2003;98(6):1169-1178.
9. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 2004;22(11):2141-2149.
10. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10-30.
11. Benoit RM, Naslund MJ, Cohen JK. Complications after radical retropubic prostatectomy in the medicare population. Urology 2000;56(1):116-120.
12. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. Jama 2000;283(3):354-360.
13. Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Forman J, Pontes JE, Wood DP, Jr. Salvage surgery or salvage radiotherapy for locally recurrent prostate cancer. Urology 1998;52(2):224-229.
14. Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, Babaian RJ. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 1997;157(3):921-925.
15. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, Larson TR, Wilkes MM, Navickis RJ. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1):2-10.
16. Perrotte P, Litwin MS, McGuire EJ, Scott SM, von Eschenbach AC, Pisters LL. Quality of life after salvage cryotherapy: The impact of treatment parameters. J Urol 1999;162(2):398-402.
17. Vaidya A, Soloway MS. Salvage radical prostatectomy for radiorecurrent prostate cancer: Morbidity revisited. J Urol 2000;164(6):1998-2001.
18. Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol 1999;5(3):139-142.
19. Lee F, Bahn DK, Siders DB, Greene C. The role of TRUS-guided biopsies for determination of internal and external spread of prostate cancer. Semin Urol Oncol 1998;16(3):129-136.
20. Chang SC, Buonaccorsi G, MacRobert A, Bown SG. Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Int J Cancer 1996;67(4):555-562.
21. Chang SC, Buonaccorsi GA, MacRobert AJ, Bown SG. Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX. Prostate 1997;32(2):89-98.
22. Chang SC, Chern IF, Hsu YH. Biological responses of dog prostate and adjacent structures after meso-tetra-(m-hydroxyphenyl) chlorin and aluminum disulfonated phthalocyanine based photodynamic therapy. Proc Natl Sci Counc Repub China B 1999;23(4):158-166.
23. Chen Q, Huang Z, Luck D, Beckers J, Brun PH, Wilson BC, Scherz A, Salomon Y, Hetzel FW. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers. Photochem Photobiol 2002;76(4):438-445.
24. Hsi RA, Kapatkin A, Strandberg J, Zhu T, Vulcan T, Solonenko M, Rodriguez C, Chang J, Saunders M, Mason N, Hahn S. Photodynamic therapy in the canine prostate using motexafin lutetium. Clin Cancer Res 2001;7(3):651-660.
25. Lee LK, Whitehurst C, Chen Q, Pantelides ML, Hetzel FW, Moore JV. Interstitial photodynamic therapy in the canine prostate. Br J Urol 1997;80(6):898-902.
26. Selman SH, Albrecht D, Keck RW, Brennan P, Kondo S. Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate. J Urol 2001;165(5):1795-1801.
27. Selman SH, Keck RW. The effect of transurethral light on the canine prostate after sensitization with the photosensitizer tin (II) etiopurpurin dichloride: A pilot study. J Urol 1994;152(6 Pt 1):2129-2132.
28. Selman SH, Keck RW, Hampton JA. Transperineal photodynamic ablation of the canine prostate. J Urol 1996;156(1):258-260.
29. Zaak D, Sroka R, Stocker S, Bise K, Lein M, Hoppner M, Frimberger D, Schneede P, Reich O, Kriegmair M, Knuchel R, Baumgartner R, Hofstetter A. Photodynamic therapy of prostate cancer by means of 5-aminolevulinic acid-induced protoporphyrin IX-In vivo experiments on the dunning rat tumor model. Urol Int 2004;72(3):196-202.
30. Chen Q, Hetzel FW. Laser dosimetry studies in the prostate. J Clin Laser Med Surg 1998;16(1):9-12.
31. Chen Q, Wilson BC, Shetty SD, Patterson MS, Cerny JC, Hetzel FW. Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. Radiat Res 1997;147(1):86-91.
32. Lee LK, Whitehurst C, Pantelides ML, Moore JV. In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland. Photochem Photobiol 1995;62(5):882-886.
33. Arnfield MR, Tulip J, Chetner M, McPhee MS. Optical dosimetry for interstitial photodynamic therapy. Med Phys 1989;16(4):602-608.
34. Fenning MC, Brown DQ, Chapman JD. Photodosimetry of interstitial light delivery to solid tumors. Med Phys 1994;21(7):1149-1156.
35. Busch TM, Wileyto EP, Emanuele MJ, Del Piero F, Marconato L, Glatstein E, Koch CJ. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. Cancer Res 2002;62(24):7273-7279.
36. Solonenko M, Cheung R, Busch TM, Kachur A, Griffin GM, Vulcan T, Zhu TC, Wang HW, Hahn SM, Yodh AG. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates. Phys Med Biol 2002;47(6):857-873.
37. Zhu TC, Dimofte A, Finlay JC, Stripp D, Busch T, Miles J, Whittington R, Malkowicz SB, Tochner Z, Glatstein E, Hahn / SNM> SM. Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy. Photochem Photobiol 2005;81(1):96-105.
38. Zhu TC, Finlay JC, Hahn SM. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. J Photochem Photobiol B 2005;79(3):231-241.
39. Sessler JL, Miller RA. Texaphyrins: New drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000;59(7):733-739.
40. Young SW, Woodburn KW, Wright M, Mody TD, Fan Q, Sessler JL, Dow WC, Miller RA. Lutetium texaphyrin (PCI-0123): A near-infrared, water-soluble photosensitizer. Photochem Photobiol 1996;63(6):892-897.
41. Mody TD, Fu L, Sessler JL. Texaphyrins: Synthesis and development of a novel class of therapeutic agents. In: Karlin KD, editor. Progress in inorganic chemistry. Chichester: John Wiley & Sons, Ltd. 2001: pp 551-598.
42. Woodburn KW, Fan Q, Kessel D, Luo Y, Young SW. Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin. J Invest Dermatol 1998;110(5):746-751.
43. Marijnissen JP, Star WM. Calibration of isotropic light dosimetry probes based on scattering bulbs in clear media. Phys Med Biol 1996;41(7):1191-1208.
44. Baas P, Murrer L, Zoetmulder FA, Stewart FA, Ris HB, van Zandwijk N, Peterse JL, Rutgers EJ. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 1997;76(6):819-826.
45. Zhu TC, Hahn SM, Kapatkin AS, Dimofte A, Rodriguez CE, Vulcan TG, Glatstein E, Hsi RA. In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol 2003;77(1):81-88.
46. Busch TM, Hahn SM, Evans SM, Koch CJ. Depletion of tumor oxygenation during photodynamic therapy: Detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide]. Cancer Res 2000;60(10):2636-2642.
47. Wang HW, Putt ME, Emanuele MJ, Shin DB, Glatstein E, Yodh AG, Busch TM. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome. Cancer Res 2004;64(20):7553-7561.
48. Yu G, Durduran T, Zhou C, Wang HW, Putt ME, Saunders HM, Sehgal CM, Glatstein E, Yodh AG, Busch TM. Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy. Clin Cancer Res 2005;11(9):3543-3552.
49. Cheung C, Culver JP, Takahashi K, Greenberg JH, Yodh AG. In vivo cerebrovascular measurement combining diffuse near-infrared absorption and correlation spectroscopies. Phys Med Biol 2001;46(8):2053-2065.
50. Culver JP, Durduran T, Cheung C, Furuya D, Greenberg JH, Yodh AG. Diffuse optical measurement of hemoglobin and cerebral blood flow in rat brain during hypercapnia, hypoxia and cardiac arrest. Adv Exp Med Biol 2003;510:293-297.
51. Durduran T, Yu G, Burnett MG, Detre JA, Greenberg JH, Wang J, Zhou C, Yodh AG. Diffuse optical measurement of blood flow, blood oxygenation, and metabolism in a human brain during sensorimotor cortex activation. Opt Lett 2004;29(15):1766-1768.
52. Menon C, Polin GM, Prabakaran I, Hsi A, Cheung C, Culver JP, Pingpank JF, Sehgal CS, Yodh AG, Buerk DG, Fraker DL. An integrated approach to measuring tumor oxygen status using human melanoma xenografts as a model. Cancer Res 2003;63(21):7232-7240.
53. Yu G, Durduran T, Lech G, Zhou C, Chance B, Mohler ER, III, Yodh AG. Time-dependent blood flow and oxygenation in human skeletal muscles measured with noninvasive near-infrared diffuse optical spectroscopies. J Biomed Opt 2005;10(2):024027.
54. Yu G, Durduran T, Zhou C, Zhu TC, Finlay JC, Busch TM, Malkowicz SB, Hahn SM, Yodh AG. Real-time insitu monitoring of human prostate photodynamic therapy with diffuse light. Photochem Photobiol 2006: Oct 1: [E Pub].
55. Friedberg JS, Mick R, Stevenson JP, Zhu T, Busch TM, Shin D, Smith D, Culligan M, Dimofte A, Glatstein E, Hahn SM. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol 2004;22(11):2192-2201.
56. Vulcan TG, Zhu TC, Rodriguez CE, Hsi A, Fraker DL, Baas P, Murrer LH, Star WM, Glatstein E, Yodh AG, Hahn SM. Comparison between isotropic and nonisotropic dosimetry systems during intraperitoneal photodynamic therapy. Lasers Surg Med 2000;26(3):292-301.